| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Glucocorticoid | 31 | 2024 | 135 | 9.400 |
Why?
|
| Immediate-Early Proteins | 18 | 2014 | 164 | 3.590 |
Why?
|
| Breast Neoplasms | 38 | 2024 | 3021 | 3.030 |
Why?
|
| Mammary Neoplasms, Experimental | 12 | 2016 | 127 | 2.080 |
Why?
|
| Triple Negative Breast Neoplasms | 6 | 2024 | 168 | 2.050 |
Why?
|
| Receptors, Estrogen | 11 | 2024 | 394 | 1.970 |
Why?
|
| Glucocorticoids | 8 | 2024 | 357 | 1.820 |
Why?
|
| Paclitaxel | 8 | 2016 | 474 | 1.670 |
Why?
|
| Mammary Glands, Animal | 11 | 2020 | 80 | 1.620 |
Why?
|
| Dexamethasone | 11 | 2015 | 343 | 1.280 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2024 | 485 | 1.250 |
Why?
|
| Apoptosis | 17 | 2019 | 1718 | 1.190 |
Why?
|
| Ovarian Neoplasms | 4 | 2024 | 771 | 1.190 |
Why?
|
| Adipose Tissue | 3 | 2016 | 262 | 1.180 |
Why?
|
| Mifepristone | 6 | 2015 | 33 | 1.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2024 | 1283 | 1.140 |
Why?
|
| Signal Transduction | 19 | 2024 | 3403 | 1.090 |
Why?
|
| Cell Line, Tumor | 17 | 2024 | 2587 | 1.000 |
Why?
|
| Epithelial Cells | 9 | 2018 | 689 | 0.980 |
Why?
|
| Phenylthiohydantoin | 3 | 2024 | 46 | 0.960 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2024 | 105 | 0.940 |
Why?
|
| Benzamides | 3 | 2024 | 234 | 0.910 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 75 | 0.890 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 135 | 0.880 |
Why?
|
| Female | 66 | 2024 | 46572 | 0.870 |
Why?
|
| Carboplatin | 1 | 2024 | 312 | 0.860 |
Why?
|
| Social Isolation | 4 | 2013 | 67 | 0.840 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2016 | 47 | 0.810 |
Why?
|
| Animals | 46 | 2024 | 27526 | 0.800 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2024 | 51 | 0.790 |
Why?
|
| Mice | 29 | 2024 | 11851 | 0.790 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 312 | 0.770 |
Why?
|
| Gene Expression Profiling | 7 | 2019 | 1452 | 0.750 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 2000 | 0.750 |
Why?
|
| Mastodynia | 1 | 2020 | 1 | 0.730 |
Why?
|
| Breast Cyst | 1 | 2020 | 4 | 0.730 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 476 | 0.730 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2014 | 693 | 0.700 |
Why?
|
| Neoplasm Proteins | 3 | 2017 | 538 | 0.690 |
Why?
|
| Estrogen Receptor alpha | 3 | 2015 | 148 | 0.690 |
Why?
|
| Immunohistochemistry | 10 | 2024 | 1801 | 0.670 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2013 | 274 | 0.650 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2008 | 108 | 0.650 |
Why?
|
| Humans | 69 | 2024 | 89925 | 0.650 |
Why?
|
| Gene Expression Regulation | 4 | 2015 | 1983 | 0.650 |
Why?
|
| Dual Specificity Phosphatase 1 | 5 | 2013 | 17 | 0.640 |
Why?
|
| Adipocytes | 3 | 2015 | 163 | 0.620 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2019 | 3470 | 0.610 |
Why?
|
| Receptors, Androgen | 7 | 2024 | 119 | 0.590 |
Why?
|
| Cell Survival | 11 | 2018 | 983 | 0.590 |
Why?
|
| Fatty Acids | 2 | 2018 | 134 | 0.580 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 605 | 0.550 |
Why?
|
| Phosphoprotein Phosphatases | 3 | 2006 | 58 | 0.540 |
Why?
|
| Chromatin | 1 | 2019 | 403 | 0.540 |
Why?
|
| Forkhead Transcription Factors | 2 | 2008 | 171 | 0.520 |
Why?
|
| Ubiquitin | 2 | 2006 | 96 | 0.520 |
Why?
|
| Carcinogenesis | 4 | 2024 | 213 | 0.520 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2012 | 268 | 0.510 |
Why?
|
| Subcutaneous Fat | 1 | 2015 | 22 | 0.510 |
Why?
|
| Lysophospholipids | 1 | 2016 | 66 | 0.510 |
Why?
|
| Triazoles | 1 | 2016 | 104 | 0.500 |
Why?
|
| RNA, Messenger | 10 | 2024 | 2026 | 0.490 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2014 | 28 | 0.460 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 2331 | 0.460 |
Why?
|
| Albumins | 1 | 2014 | 129 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 2506 | 0.450 |
Why?
|
| Hormone Antagonists | 1 | 2013 | 19 | 0.450 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 29 | 0.440 |
Why?
|
| Nuclear Proteins | 3 | 2004 | 727 | 0.440 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2014 | 885 | 0.440 |
Why?
|
| Cell Proliferation | 7 | 2019 | 1669 | 0.440 |
Why?
|
| Mammary Neoplasms, Animal | 5 | 2020 | 57 | 0.440 |
Why?
|
| Prostatic Neoplasms | 5 | 2021 | 1738 | 0.440 |
Why?
|
| Cell Cycle Proteins | 3 | 2004 | 399 | 0.430 |
Why?
|
| Antigens, Polyomavirus Transforming | 5 | 2015 | 47 | 0.430 |
Why?
|
| Chelating Agents | 1 | 2013 | 69 | 0.430 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 315 | 0.420 |
Why?
|
| Calcium Signaling | 1 | 2013 | 138 | 0.420 |
Why?
|
| Pituitary-Adrenal System | 1 | 2012 | 64 | 0.410 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2013 | 73 | 0.410 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 137 | 0.410 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 142 | 0.410 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2012 | 81 | 0.410 |
Why?
|
| Neoplasms | 3 | 2021 | 3065 | 0.400 |
Why?
|
| Breast | 8 | 2021 | 292 | 0.400 |
Why?
|
| Mice, SCID | 4 | 2015 | 259 | 0.390 |
Why?
|
| Multiprotein Complexes | 2 | 2012 | 96 | 0.390 |
Why?
|
| Receptors, Progesterone | 3 | 2011 | 175 | 0.380 |
Why?
|
| Prognosis | 11 | 2024 | 3796 | 0.380 |
Why?
|
| Up-Regulation | 2 | 2013 | 726 | 0.370 |
Why?
|
| Stress, Psychological | 4 | 2021 | 322 | 0.370 |
Why?
|
| Inflammation | 2 | 2021 | 981 | 0.370 |
Why?
|
| Carcinoma | 2 | 2011 | 438 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2017 | 1352 | 0.350 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 1544 | 0.350 |
Why?
|
| Mitochondria | 1 | 2013 | 556 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2006 | 226 | 0.340 |
Why?
|
| Mutation | 4 | 2019 | 4165 | 0.340 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2021 | 449 | 0.330 |
Why?
|
| Tumor Cells, Cultured | 7 | 2013 | 1048 | 0.330 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 117 | 0.330 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2017 | 122 | 0.330 |
Why?
|
| Receptor, ErbB-2 | 3 | 2017 | 247 | 0.320 |
Why?
|
| Transcription, Genetic | 6 | 2019 | 1158 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2003 | 194 | 0.320 |
Why?
|
| Calcium | 1 | 2013 | 1179 | 0.310 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 119 | 0.300 |
Why?
|
| Adult | 17 | 2024 | 26811 | 0.300 |
Why?
|
| Proteins | 2 | 2012 | 786 | 0.300 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2008 | 51 | 0.300 |
Why?
|
| Cell Cycle | 2 | 2019 | 508 | 0.300 |
Why?
|
| Mice, Transgenic | 10 | 2018 | 1576 | 0.300 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2004 | 46 | 0.300 |
Why?
|
| Disease Progression | 8 | 2021 | 1469 | 0.300 |
Why?
|
| Nitriles | 4 | 2024 | 156 | 0.290 |
Why?
|
| Protein Binding | 4 | 2019 | 1491 | 0.290 |
Why?
|
| Phosphorylation | 5 | 2012 | 1130 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2005 | 341 | 0.280 |
Why?
|
| Middle Aged | 17 | 2024 | 26133 | 0.280 |
Why?
|
| Aged | 16 | 2024 | 19241 | 0.280 |
Why?
|
| Biomarkers | 1 | 2013 | 1775 | 0.270 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2015 | 137 | 0.260 |
Why?
|
| Blotting, Western | 4 | 2009 | 793 | 0.260 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2006 | 173 | 0.250 |
Why?
|
| Gene Expression | 5 | 2016 | 1309 | 0.250 |
Why?
|
| Transfection | 5 | 2008 | 909 | 0.250 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 160 | 0.240 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 6780 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2004 | 412 | 0.240 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 2393 | 0.240 |
Why?
|
| Contrast Media | 3 | 2017 | 1084 | 0.240 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 374 | 0.240 |
Why?
|
| Tyramine | 1 | 2024 | 6 | 0.240 |
Why?
|
| Acetates | 1 | 2024 | 67 | 0.230 |
Why?
|
| Tamoxifen | 2 | 2003 | 168 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2020 | 603 | 0.230 |
Why?
|
| MAP Kinase Signaling System | 1 | 2004 | 198 | 0.230 |
Why?
|
| Models, Biological | 3 | 2008 | 1765 | 0.220 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2003 | 34 | 0.220 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 114 | 0.220 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 283 | 0.220 |
Why?
|
| Enzyme Activation | 4 | 2012 | 696 | 0.220 |
Why?
|
| Caspase 3 | 2 | 2013 | 162 | 0.220 |
Why?
|
| COS Cells | 3 | 2008 | 167 | 0.210 |
Why?
|
| Enzyme Induction | 3 | 2013 | 88 | 0.210 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2019 | 284 | 0.210 |
Why?
|
| Ubiquitins | 1 | 2002 | 38 | 0.210 |
Why?
|
| Cell Line | 7 | 2009 | 2495 | 0.200 |
Why?
|
| Genomics | 2 | 2019 | 779 | 0.200 |
Why?
|
| Estradiol | 1 | 2003 | 250 | 0.200 |
Why?
|
| RNA, Small Interfering | 4 | 2018 | 557 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2013 | 105 | 0.190 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 2 | 2018 | 12 | 0.190 |
Why?
|
| Sirolimus | 2 | 2012 | 162 | 0.180 |
Why?
|
| Down-Regulation | 3 | 2008 | 520 | 0.180 |
Why?
|
| Genes, myc | 1 | 2000 | 40 | 0.180 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2887 | 0.180 |
Why?
|
| Simian virus 40 | 2 | 2015 | 35 | 0.180 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 1169 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2004 | 665 | 0.170 |
Why?
|
| Mammography | 2 | 2020 | 475 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 217 | 0.170 |
Why?
|
| Transcription Factors | 2 | 2004 | 1665 | 0.170 |
Why?
|
| Arteries | 1 | 2020 | 179 | 0.160 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 368 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2012 | 145 | 0.160 |
Why?
|
| Gadolinium DTPA | 2 | 2017 | 256 | 0.160 |
Why?
|
| Random Allocation | 2 | 2018 | 327 | 0.160 |
Why?
|
| Arabidopsis Proteins | 1 | 2000 | 138 | 0.150 |
Why?
|
| Biopsy | 2 | 2020 | 1184 | 0.150 |
Why?
|
| Dietary Sugars | 1 | 2018 | 8 | 0.150 |
Why?
|
| Megestrol Acetate | 1 | 2017 | 10 | 0.150 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 31 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 476 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 172 | 0.150 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2020 | 275 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2020 | 328 | 0.150 |
Why?
|
| Forkhead Box Protein O3 | 2 | 2008 | 21 | 0.140 |
Why?
|
| Metabolome | 1 | 2017 | 51 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 2 | 2008 | 303 | 0.140 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2006 | 25 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 65 | 0.140 |
Why?
|
| Dietary Fats | 1 | 2017 | 135 | 0.140 |
Why?
|
| Rats | 7 | 2018 | 4048 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 569 | 0.130 |
Why?
|
| Interdisciplinary Communication | 2 | 2010 | 131 | 0.130 |
Why?
|
| Response Elements | 1 | 2016 | 69 | 0.130 |
Why?
|
| Algorithms | 1 | 2004 | 1908 | 0.130 |
Why?
|
| Transcriptome | 2 | 2018 | 661 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2012 | 383 | 0.130 |
Why?
|
| Binding Sites | 2 | 2009 | 1121 | 0.130 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 103 | 0.130 |
Why?
|
| Amino Acid Motifs | 2 | 2006 | 117 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2016 | 307 | 0.120 |
Why?
|
| Luciferases | 2 | 2006 | 128 | 0.120 |
Why?
|
| Embryo, Mammalian | 1 | 1995 | 223 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 404 | 0.120 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 52 | 0.120 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 81 | 0.120 |
Why?
|
| Lymph Nodes | 2 | 2015 | 550 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2015 | 1255 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 2 | 2006 | 255 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 208 | 0.120 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2013 | 51 | 0.120 |
Why?
|
| Coconut Oil | 1 | 2014 | 4 | 0.120 |
Why?
|
| Plant Oils | 1 | 2014 | 9 | 0.120 |
Why?
|
| Protein Phosphatase 1 | 2 | 2004 | 34 | 0.120 |
Why?
|
| Fibroblasts | 3 | 2006 | 759 | 0.120 |
Why?
|
| Cell Death | 1 | 2015 | 261 | 0.120 |
Why?
|
| Caspase 7 | 1 | 2013 | 15 | 0.110 |
Why?
|
| Mitochondrial Membranes | 1 | 2013 | 15 | 0.110 |
Why?
|
| Caloric Tests | 1 | 2013 | 6 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2017 | 542 | 0.110 |
Why?
|
| Lipogenesis | 1 | 2013 | 23 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1533 | 0.110 |
Why?
|
| Necrosis | 1 | 2013 | 210 | 0.110 |
Why?
|
| Leptin | 1 | 2013 | 102 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 397 | 0.100 |
Why?
|
| Furans | 1 | 2012 | 16 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 432 | 0.100 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Food | 1 | 2013 | 89 | 0.100 |
Why?
|
| Enzyme Activators | 1 | 2012 | 14 | 0.100 |
Why?
|
| Thapsigargin | 1 | 2012 | 55 | 0.100 |
Why?
|
| Male | 7 | 2024 | 42658 | 0.100 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 30 | 0.100 |
Why?
|
| Hypothalamus | 1 | 2012 | 79 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 374 | 0.100 |
Why?
|
| Time Factors | 4 | 2012 | 5357 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 869 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 338 | 0.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 36 | 0.090 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 126 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 189 | 0.090 |
Why?
|
| bcl-X Protein | 3 | 2006 | 53 | 0.090 |
Why?
|
| Cyclins | 2 | 2004 | 82 | 0.090 |
Why?
|
| Chromones | 2 | 2008 | 31 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 346 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2004 | 79 | 0.090 |
Why?
|
| Stress, Physiological | 2 | 2009 | 232 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 961 | 0.090 |
Why?
|
| Morpholines | 2 | 2008 | 70 | 0.090 |
Why?
|
| Pyridines | 1 | 2012 | 300 | 0.090 |
Why?
|
| Glucose | 1 | 2013 | 629 | 0.090 |
Why?
|
| Group Processes | 1 | 2010 | 31 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 29 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 1066 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2014 | 1315 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2012 | 371 | 0.080 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2009 | 19 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1929 | 0.080 |
Why?
|
| Neurosecretory Systems | 1 | 2009 | 36 | 0.080 |
Why?
|
| Gadolinium | 1 | 2009 | 103 | 0.080 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2009 | 6 | 0.080 |
Why?
|
| Placebos | 1 | 2009 | 211 | 0.080 |
Why?
|
| Enzyme Inhibitors | 3 | 2008 | 644 | 0.080 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2009 | 61 | 0.080 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2008 | 64 | 0.080 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 2063 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 125 | 0.080 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 13 | 0.080 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1988 | 4 | 0.080 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 7 | 0.080 |
Why?
|
| Benzoquinones | 1 | 2008 | 26 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 1008 | 0.080 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2008 | 47 | 0.080 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 42 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 200 | 0.080 |
Why?
|
| Mammary Glands, Human | 1 | 2008 | 24 | 0.080 |
Why?
|
| Social Environment | 2 | 2009 | 187 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2010 | 191 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 3024 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 156 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 586 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2020 | 310 | 0.070 |
Why?
|
| Kinetics | 2 | 2017 | 1534 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 1 | 1988 | 142 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2008 | 144 | 0.070 |
Why?
|
| Conserved Sequence | 1 | 2008 | 211 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2017 | 9203 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2009 | 687 | 0.070 |
Why?
|
| Insulin | 1 | 2012 | 1148 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2015 | 2015 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2008 | 130 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3252 | 0.070 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2006 | 14 | 0.070 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2006 | 13 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 495 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2006 | 21 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 122 | 0.070 |
Why?
|
| Phenotype | 3 | 2019 | 2457 | 0.070 |
Why?
|
| Catalytic Domain | 1 | 2006 | 156 | 0.070 |
Why?
|
| Injections | 2 | 2017 | 116 | 0.060 |
Why?
|
| Alleles | 1 | 2009 | 1139 | 0.060 |
Why?
|
| Young Adult | 3 | 2017 | 6408 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 323 | 0.060 |
Why?
|
| Base Sequence | 1 | 2009 | 2329 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2008 | 443 | 0.060 |
Why?
|
| DNA Primers | 1 | 2006 | 543 | 0.060 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2004 | 8 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 70 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 77 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2004 | 258 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 112 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2006 | 690 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 98 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 1898 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2004 | 274 | 0.060 |
Why?
|
| Liver | 1 | 2008 | 1211 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2017 | 816 | 0.060 |
Why?
|
| Age Factors | 1 | 2008 | 1880 | 0.060 |
Why?
|
| DNA | 1 | 2009 | 1311 | 0.050 |
Why?
|
| Benzopyrans | 1 | 2003 | 12 | 0.050 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 10 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 117 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 173 | 0.050 |
Why?
|
| Propionates | 1 | 2003 | 33 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2003 | 48 | 0.050 |
Why?
|
| Thiophenes | 1 | 2003 | 43 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2003 | 126 | 0.050 |
Why?
|
| Computational Biology | 1 | 2006 | 551 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2002 | 53 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2004 | 381 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 64 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 87 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2009 | 1380 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2003 | 293 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2006 | 425 | 0.050 |
Why?
|
| Psychophysiology | 1 | 2021 | 6 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 1237 | 0.050 |
Why?
|
| Piperidines | 1 | 2003 | 163 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2004 | 286 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 294 | 0.050 |
Why?
|
| Oncogene Addiction | 1 | 2021 | 2 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2008 | 1175 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2004 | 440 | 0.050 |
Why?
|
| Indoles | 1 | 2003 | 300 | 0.050 |
Why?
|
| Growth Substances | 1 | 2001 | 79 | 0.050 |
Why?
|
| Hormones | 1 | 2021 | 139 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2004 | 576 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 2416 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 434 | 0.040 |
Why?
|
| Fatty Acid Desaturases | 1 | 2000 | 17 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2363 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 198 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2004 | 1102 | 0.040 |
Why?
|
| fas Receptor | 1 | 2000 | 77 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 657 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 372 | 0.040 |
Why?
|
| DNA Damage | 1 | 2021 | 373 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2002 | 677 | 0.040 |
Why?
|
| DNA Repair | 1 | 2021 | 363 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 5555 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1244 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 347 | 0.040 |
Why?
|
| Troleandomycin | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 5 | 0.040 |
Why?
|
| Glucuronides | 1 | 2017 | 34 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2019 | 95 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 42 | 0.040 |
Why?
|
| Ketoconazole | 1 | 2017 | 24 | 0.040 |
Why?
|
| Microsomes, Liver | 1 | 2017 | 49 | 0.040 |
Why?
|
| Fructose | 1 | 2018 | 36 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2017 | 75 | 0.040 |
Why?
|
| Weaning | 1 | 2017 | 25 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 1134 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1997 | 46 | 0.040 |
Why?
|
| Adiposity | 1 | 2017 | 76 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 521 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2017 | 352 | 0.030 |
Why?
|
| Remission Induction | 2 | 2011 | 741 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1997 | 80 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2006 | 1704 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 1996 | 67 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 388 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 417 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1731 | 0.030 |
Why?
|
| Etoposide | 1 | 1996 | 206 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 234 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 1996 | 192 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 338 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1996 | 212 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 1996 | 205 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 1995 | 100 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 262 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1497 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1083 | 0.030 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cisplatin | 1 | 1996 | 598 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2014 | 20 | 0.030 |
Why?
|
| Cell Division | 1 | 1995 | 692 | 0.030 |
Why?
|
| Benzoates | 1 | 2014 | 33 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 104 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 865 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 272 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 91 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 778 | 0.030 |
Why?
|
| Perfusion | 1 | 2014 | 253 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 808 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 376 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 565 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 646 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 691 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2010 | 29 | 0.020 |
Why?
|
| Endocrine Glands | 1 | 2009 | 13 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2011 | 171 | 0.020 |
Why?
|
| Corticosterone | 1 | 2009 | 35 | 0.020 |
Why?
|
| United States | 2 | 2017 | 7102 | 0.020 |
Why?
|
| Health Services Research | 1 | 2010 | 138 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 121 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2009 | 130 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2767 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 179 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 8270 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 2327 | 0.020 |
Why?
|
| Ovary | 1 | 2009 | 262 | 0.020 |
Why?
|
| Microscopy | 1 | 2008 | 87 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1988 | 72 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1145 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 376 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1988 | 109 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1988 | 308 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 166 | 0.020 |
Why?
|
| Spleen | 1 | 1988 | 433 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2009 | 380 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 785 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 871 | 0.020 |
Why?
|
| Radiodermatitis | 1 | 2005 | 10 | 0.020 |
Why?
|
| Hypertension | 1 | 2011 | 747 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1988 | 754 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1988 | 958 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 399 | 0.010 |
Why?
|
| Arousal | 1 | 2005 | 170 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 302 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 744 | 0.010 |
Why?
|
| Butadienes | 1 | 2003 | 34 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1988 | 740 | 0.010 |
Why?
|
| Mammaplasty | 1 | 2005 | 110 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 25 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 42 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 361 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 755 | 0.010 |
Why?
|
| Quinazolines | 1 | 2003 | 212 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 136 | 0.010 |
Why?
|
| Research | 1 | 2003 | 251 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1988 | 1221 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 811 | 0.010 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 1997 | 3 | 0.010 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 1997 | 25 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1997 | 48 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 1997 | 52 | 0.010 |
Why?
|
| Androstadienes | 1 | 1997 | 72 | 0.010 |
Why?
|
| ras Proteins | 1 | 1997 | 130 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 453 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 919 | 0.010 |
Why?
|